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Background: Optimised two-dose human papillomavirus (HPV) vaccine schedules are now endorsed for
young adolescents by the World Health Organization. Limited data are available about effectiveness of
o3 doses using a standard dose schedule.
Methods: Deterministic data linkage was undertaken between the Victorian Cervical Cytology Registry
and National HPV Vaccination Program Register to determine quadrivalent HPV vaccination status and
incidence of cervical pathology among vaccine eligible women (aged 26 years or younger in 2007)
screened in Victoria, Australia between April 2007 and December 2011. Proportional hazards regression
was used to estimate hazard ratios (HR) adjusted for age, socioeconomic status and area of residence.
Women were stratiﬁed into those vaccinated before or after ﬁrst screen.
Results: Any number of doses (1, 2 or 3) were associated with lower rates of high grade and low grade
cytology diagnoses as long as doses were given before screening commencement (one dose HR high
grade 0.44 (95% CI 0.32–0.59), one dose low grade 0.48 (95% CI 0.40–0.58); two doses HR high grade 0.63
(95% CI 0.50–0.80), HR low grade 0.52 (95% CI 0.44–0.61); three doses HR high grade 0.53 (95% CI 0.47–
0.60), HR low grade 0.73 (95% CI 0.68–0.78)). Three doses of vaccine, but not fewer, were associated with
reduced risk of high grade histologically conﬁrmed abnormality in this cohort, regardless of whether
vaccination occurred before or after screening (HR before 0.71 (95% CI 0.64–0.80), HR after 0.87 (95% CI
0.82–0.93)). Secondary analyses censoring end points occurring within 1, 6, 12, or 24 months of ﬁnal
vaccine dose suggested an increasing effect of partial vaccination courses over time.
Conclusion: Our data suggest that less than three doses of quadrivalent HPV vaccine provides some
protection against cervical intraepithelial neoplasia, even when measured within 5 years in a population
including those who were sexually active at the time of vaccination.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Between 2007 and 2009, Australia vaccinated over half of its
young women aged 12–26 years against human papillomavirus
(HPV) types 6, 11, 16 and 18 using the quadrivalent HPV vaccine
[1]. These HPV types cause over 90% of genital warts, 35% of low-
grade cervical intraepithelial neoplasia (CIN), 50–60% of high-
grade CIN (higher in younger women) and 70–80% of cervical
cancers [2,3]. The vaccine was provided through both school-
based programs and community providers, who were predomi-
nantly general practitioners. It remains the world's most broadly
targeted funded HPV vaccination catch up program. The three-
dose course was generally offered at the recommended spacing of
0, 2 and 6 months, with an accelerated schedule of 0, 1 and
4 months also used in the ﬁrst year of the program in order to
facilitate course completion within the school year. However, not
all women completed the course, with dose 1 coverage in the
population at least 15% higher than dose 3 coverage across the age
range [1,4]. Reasons for this apparent failure to complete the
course include school absence, lack of awareness of the need to
complete three doses, interruption by pregnancy or travel, simply
forgetting and under reporting of the ﬁnal dose(s) to the register
[1,5–7].
On the basis of immunogenicity1 data from randomised trials,
optimised two dose schedules (using a prime-boost spacing of at
least 6 months between doses) have now been endorsed by the
World Health Organisation for use in females o15 years of age for
both HPV vaccines. It is possible that even one dose of vaccine may
be protective, with the recent hypothesis from Schiller and Lowy
that the repetitive antigen display on the virus like particles
stimulates an immune response that is more similar to that
induced by a viral infection or attenuated live virus vaccine than
a sub-unit vaccine [8].
Given that Australia has a considerable population of women
who have only received one or two doses of the vaccine, we aimed
to estimate the effectiveness of one or two doses of HPV vaccine
against cervical abnormalities when administered as the ﬁrst
dose/s in a standard HPV vaccination schedule.
2. Methods
2.1. Data linkage and cohort assembly
As described previously, we undertook a deterministic data
linkage between the Victorian Cervical Cytology Registry (VCCR)
and the National HPV Vaccination Program Register (NHVPR) for
vaccine age-eligible women resident in Victoria, Australia [9,10].
These registers, operating under opt-off consent, hold records of
cervical screening tests and HPV vaccination doses for individual
women. Brieﬂy, identifying data was extracted and de-identiﬁed
from each register in a similar manner and the Australian Institute
of Health and Welfare's (AIHW's) data linkage unit generated
varying combinations of perturbed details (such as selected letters
from given name and surname, perturbed date of birth, postcode,
parts of the Medicare number) and ascertained the best linkage
pair combinations to achieve correct matching of unique indivi-
duals. For linked records, an identifying key was provided to each
record set to allow analytical data ﬁelds from each register to be
matched to the ﬁelds from the other register. Women who had a
record identiﬁed in each register were thus identiﬁed as being
both vaccinated and screened, whereas other women had either a
screening or vaccination record only. In this analysis we only
consider records for women with a screening history, creating a
cohort of screened women, who may or may not be vaccinated. A
retrospective cohort was constructed of women aged 26 or
younger in 2007 (funded vaccine eligible) who had a Pap test
recorded on the VCCR during the study period, 1 April 2007 (the
date the HPV vaccination program commenced) to 31 December
2011. Women were counted as at risk of a diagnosis of a cervical
abnormality from the time they commenced cervical screening,
and were entered into the cohort at their ﬁrst Pap test (or on
1 April 2007 if their ﬁrst Pap test was prior to that time). Women
were followed until the outcome of interest, date of death,
hysterectomy or the end of the study period.
2.2. Outcome measures
The primary outcome was histologically conﬁrmed high-grade
(HG) cervical disease (CIN2þ/AIS), deﬁned as CIN2, CIN3 and
adenocarcinoma in situ or mixed CIN3/AIS. We also considered
histologically conﬁrmed CIN3 and CIN2. We also examined the
cytologically predicted abnormalities grouped as low-grade (pos-
sible LSIL, LSIL according to the Australian Modiﬁed Bethesda
Classiﬁcation) and high-grade (possible HSIL, HSIL, HGIL, possible
HGIL). Histological and cytological outcomes were assigned
according to categorisation used by the AIHW [11] and Australian
Standardised Modiﬁed Bethesda System, respectively [12]. For all
outcomes, a woman's ﬁrst relevant abnormality or her ﬁrst in two
years with at least two negative cytology tests in between was
counted.
2.3. Vaccination status and censorship before vaccine course
completion
Vaccination status was deﬁned as the number of doses received
in accordance with the Chief Medical Ofﬁcer of Australia's guide-
lines [13] (0, 1, 2, 3) with vaccination status deﬁned as at the date
1 Abbreviations: Victorian Cervical Cytology Registry (VCCR); National HPV
Vaccination Program Register (NHVPR); Australian Institute of Health and Welfare
(AIHW).
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of diagnosis of the cytological abnormality or, in the case of
histology, at the date of the abnormal cytology preceding the
histological diagnosis. Where cytology was performed on the day
of vaccination, the previous period's vaccination status was
assigned (i.e. number of doses – 1). Where women received three
doses but those doses were given outside the recommended
intervals (too close) and no fourth dose was given (designated as
‘not clinically complete’), they were excluded from the analysis.
In this analysis we censored all events occurring during the
vaccination course. Using this method, end points assigned to one
or two doses are those of women who were only ever partially
vaccinated (received one or two doses only) in the study period,
reﬂecting the effectiveness of partial vaccination more accurately
than if all cumulative time accruing for women who experience
short amounts of time in receipt of one or two doses on the way to
three dose vaccination are included. In our primary analysis we
did not utilise any further lag periods once the ﬁnal dose was
received before commencing case counting, to reﬂect what would
be observed by women and their clinicians. In a secondary
analysis, we censored events occurring during the time period
between the woman's ﬁnal dose and one, six, 12 and 24 months
after the woman's ﬁnal dose to recognise that the abnormalities
observed in the early periods following vaccination are likely to be
the result of pre-existing HPV infection.
2.4. Data analysis
We stratiﬁed and/or adjusted all analyses by age, given that age
is a strong predictor of the likelihood of sexual activity, diagnosis
of a cervical abnormality and, in this cohort, age at vaccination.
Together these factors mean that vaccine effectiveness will be
higher in women in the cohort who are younger, as previously
demonstrated [9].
We used Cox proportional hazard regression, with age as the
time axis, to estimate hazard ratios (with 95% CIs) of cervical
abnormalities for women in our cohort according to their vaccina-
tion status. Using age as the time axis allows the baseline hazard
to change as a function of age, which is a better method for
controlling the potential confounding due to age [14]. As we only
had the month and year of each individual's date of birth, to
calculate their age we made the assumption that their date of birth
was on the 15th day of each month.
For the regression analysis, women were categorised into the age
groups 12–16 years, 17–19 years, 20–23 years and 24–26 years (as at
2007, when the vaccine program commenced), approximately repre-
senting women of school age, school leaving age and young and mid-
20s. These groups differed broadly in completion rates of the vaccine
course, due to differing modes or issues in delivering the vaccine, as
well as approximating timing of sexual debut. We also stratiﬁed
women according to whether they were participating in screening
prior to vaccination or afterwards. As cervical screening is only
indicated in sexually active women (Australian guidelines state from
the age of 18 years or two years after ﬁrst intercourse (whichever is
later)), we used this as a proxy measure for the occurrence of sexual
activity prior to vaccination, implying that women vaccinated before
they started screening were more likely to be HPV naïve at vaccina-
tion. We refer in this manuscript to two groups of women: Those
who received their ﬁnal vaccine dose before screening (“before”
group) and those who received their ﬁnal vaccine dose after they had
commenced screening (“after” group).
Where overall estimates are made, these are adjusted for age
(categorised or in single years, depending on the outcome and
according to best ﬁt for the model). We also adjusted a priori for
socioeconomic status and area of remoteness using standard
Australian area based measures assigned through postcode of
residence [15,16]. The assumption of proportional hazards was
not violated for any of the abnormality outcomes.
We also assessed whether there was any difference in vaccine
effectiveness of two doses against high-grade histological outcomes
according to the number of days between the doses, with the a priori
hypothesis that a longer lag time would produce a superior immune
response and therefore greater protection. We compared women
with spacing between the two doses of less than 6 months with
those with a spacing of 6 months or greater (the recommended dose
spacing for licensed two dose courses), noting a median difference of
114 days (SD 128 days) between doses in our population.
Analyses of demographic and exposure characteristics of
women in the cohort by vaccination status used the Mann–
Whitney U test for ordinal variables and the Pearson chi-square
test for nominal variables. Detection rates were calculated as the
number of events per 1000 person–years at risk.
In a non HPV-naïve population, the relative effectiveness of
HPV vaccination increases over time from the date of vaccination,
as prevalent lesions are detected and treated or cleared and
incident lesions occur in the unvaccinated women but not the
vaccinated women [17]. Therefore, we also evaluated the observed
effectiveness of vaccination by number of doses and screening
pre-/post-vaccination over time using Kaplan–Meier failure prob-
ability plots. Failure time was calculated as the number of months
from the time of their ﬁrst Pap test or last vaccination dose (which
ever was later) until their outcome of interest or time of censoring.
Statistical analyses were performed using Stata/SE 12.1 (Stat-
Corp LP., College Station, TX).
Ethics approval was obtained from the Department of Health
and Ageing and the Australian Institute of Health and Welfare's
Human Research and Ethics Committees. Approval for use of
NHVPR data was given by the Department of Health and Ageing,
the data custodian and for the VCCR data by the Victorian
Department of Health.
3. Results
3.1. Cohort characteristics
Results of the linkage process used to create the cohort are shown
in Fig. 1. Following exclusion of those who received three doses
spaced too close together (n¼426), 289,478 women (133,055 unvac-
cinated and 156,423 with at least one dose) were included in the
analysis. Characteristics of the cohort are described in Table 1.
Maximum follow-up time was 4.75 years with an average follow-
up time of 2.89 years (average of 2.73 years for vaccinated and 3.07
years for unvaccinated women). Vaccinated women were younger
than unvaccinated women (mean age in 2007, 21.13 vs. 21.98;
po0.0001) and had a younger age at cohort entry (22.93 vs.
23.49; po0.0001) and at ﬁrst screen (20.43 vs. 21.71; po0.0001).
Unvaccinated womenwere more likely to live in a major city (80.53%
vs. 75.71%; po0.0001) and reside in areas in the lowest quintile of
socioeconomic status (18.05% vs. 15.14%; po0.0001). A greater
proportion of vaccinated women were screening prior to April
2007 (vaccine program start date) (42.43% vs. 36.19%; po0.0001).
Among vaccinated women, incompletely vaccinated women were
more likely to be participating in screening prior to their ﬁrst vaccine
dose than fully vaccinated women (1 dose 66.42%, 2 doses 61.58%,
3 doses 49.89%; po0.0001).
3.2. Outcome by vaccination status and vaccination occurrence pre-/
post-screening commencement
Overall, vaccinated women (any number of doses) had lower rates
of histologically conﬁrmed high-grade cervical abnormalities than
J.M.L. Brotherton et al. / Papillomavirus Research 1 (2015) 59–73 61
unvaccinated women as long as they received their ﬁnal vaccine dose
before commencement of screening (6.44 vs. 7.81 per 1000 person
years; adjusted hazard ratio 0.86 (95% CI 0.78–0.94)) (Table 2). This
was due to the protective effect found among fully vaccinated
women, in whom a lower rate was observed whether or not they
were vaccinated before (rate 5.37) or after (rate 6.94) their ﬁrst screen.
This effect was greatest for CIN3/AIS (HR for women completing
vaccination before screening 0.69 (95% CI 0.58–0.81)) compared with
CIN2 (HR for women completing vaccination before screening 0.75
(95% CI 0.65–0.86)). Any number of doses (1, 2 or 3) was found to be
associated with lower rates of high grade and low grade cytology
diagnoses as long as doses were given prior to screening commence-
ment (one dose HR high grade 0.44 (95% CI 0.32–0.59), one dose low
grade 0.48 (95% CI 0.40–0.58); two doses HR high grade 0.63 (95% CI
0.50–0.80), HR low grade 0.52 (95% CI 0.44–0.61); three doses HR
high grade 0.53 (95% CI 0.47–0.60), HR low grade 0.73 (95% CI 0.68–
0.78)) (Table 2). These results were fairly consistent across age groups,
although the strongest effects against cytological abnormalities were
seen in the oldest age groups in contrast to the histological outcomes,
where the youngest women had the strongest evidence of protection.
For women aged 16 and under, this protection against high-grade CIN
appeared to extend even to partial dose recipients although smaller
numbers of women in this group result in less precision in the
estimates (see Appendix A Tables A.1–A.4 for age stratiﬁed results).
3.3. Effects of dose spacing and censorship periods on outcome
measures
There was no discernible attenuation of effect for high grade
histology outcomes seen when women who received two doses
were stratiﬁed into those with 6 months or more separation
between doses and less than 6 months (Appendix A Table A.5).
However, applying censorship periods before counting end points
for high grade histology and CIN3/AIS indicated that increasing lag
times resulted in evidence of vaccine effectiveness over time for
those who received one or two doses prior to commencing
screening (Appendix A Table A.6). This is consistent with the
Kaplan–Meier failure probability plots, which indicate, most nota-
bly for CIN3/AIS histology, that the effect of partial vaccination
becomes apparent over time within the cohort (Fig. 2). By 48
months the incidence of CIN3/AIS among each of the vaccine dose
groups vaccinated prior to screening is below that of the unvacci-
nated group (Fig. 3; see Appendix B for other outcome plots).
4. Discussion
Australia's large scale HPV vaccination catch up program, and
relatively intensive cytology based cervical screening program,
Fig. 1. Data linkage process and exclusions for analysis.nnFootnote: Note that the NHVPR data for linkage included all Australian women, whereas the VCCR data only holds
records for women resident in Victoria. Approximately 470,000 Victorian females, including those too young to commence screening in the 2007–2011 period (routine age at
vaccination in ongoing program is 12–13 years), have records of vaccine doses received in the study period held on the NHVPR.
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Table 1
Summary of descriptive characteristics of entire cohort eligible for vaccine (aged 26 years or less in 2007).
Unvaccinateda Vaccinated, any dose Vaccinated, 1 dose Vaccinated, 2 doses Completely vaccinateda, 3 doses
Number of observations 133,055 156,423 20,659 27,500 108,264
Mean age in 2007 21.98 (73.16) 21.13 (73.23) 21.86 (72.82) 21.72 (72.88) 20.84 (73.34)
Mean age at ﬁrst screen 21.71 (73.42) 20.43 (72.74) 20.77 (72.96) 20.69 (72.90) 20.30 (72.64)
Mean age at entry to cohort 23.49 (72.96) 22.93 (72.86) 23.40 (72.65) 23.39 (72.69) 22.72 (72.92)
Age in 2007 (years)
r16 8005 (6.02%) 14,453 (9.24%) 797 (3.86%) 1372 (4.99%) 12,284 (11.35%)
17–19 23,066 (17.34%) 36,236 (23.17%) 3688 (17.85%) 4944 (17.98%) 27,604 (25.50%)
20–23 50,255 (37.77%) 60,992 (38.99%) 9351 (45.26%) 12,466 (45.33%) 39,175 (36.18%)
24–26 51,729 (38.88%) 44,742 (28.60%) 6823 (33.03%) 8718 (31.70%) 29,201 (26.97%)
Remoteness areab
Major cities 106,738 (80.53%) 118,381 (75.71%) 15,845 (76.72%) 20,915 (76.09%) 81,621 (75.42%)
Inner regional 21,496 (16.22%) 31,987 (20.46%) 3970 (19.22%) 5421 (19.72%) 22,596 (20.88%)
Outer regional 4261 (3.21%) 5944 (3.80%) 831 (4.02%) 1141 (4.15%) 3972 (3.67%)
Remote 55 (0.04%) 43 (0.03%) 7 (0.03%) 10 (0.04%) 26 (0.02%)
Socioeconomic statusc
1 (lowest) 23,809 (18.05%) 23,595 (15.14%) 3383 (16.43%) 4368 (15.94%) 15,844 (14.69%)
2 23,224 (17.60%) 26,669 (17.11%) 3917 (19.02%) 4834 (17.64%) 17,918 (16.61%)
3 26,097 (19.78%) 29,552 (18.96%) 4140 (20.10%) 5319 (19.41%) 20,093 (18.62%)
4 32,438 (24.59%) 40,474 (25.96%) 5062 (24.58%) 7031 (25.66%) 28,381 (26.31%)
5 (highest) 26,365 (19.98%) 35,591 (22.83%) 4091 (19.87%) 5853 (21.36%) 25,647 (23.77%)
Age at ﬁrst screen (years)
r16 4666 (3.51%) 6359 (4.07%) 962 (4.66%) 1277 (4.64%) 4120 (3.81%)
17–19 36,585 (27.50%) 60,236 (38.51%) 6942 (33.60%) 9522 (34.63%) 43,772 (40.43%)
20–23 51,137 (38.43%) 66,950 (42.80%) 8839 (42.79%) 11,787 (42.86%) 46,324 (42.79%)
24þ 40,667 (30.56%) 22,878 (14.63%) 3916 (18.96%) 4914 (17.87%) 14,048 (12.98%)
Mean number of Pap tests 2.41 (71.92) 2.75 (72.03) 2.78 (72.02) 2.82 (72.02) 2.73 (72.04)
Mean number of Pap tests by abnormality status
No abnormalities 1.95 (71.31) 2.19 (71.37) 2.19 (71.34) 2.22 (71.34) 2.18 (71.38)
1 or more abnormalities 4.22 (72.71) 4.62 (72.66) 4.51 (72.60) 4.62 (72.56) 4.65 (72.70)
Screening history
Screening before 1 April 2007 48,157 (36.19%) 66,367 (42.43%) 9576 (46.35%) 12,839 (46.69%) 43,952 (40.60%)
First screen after 1 April 2007 84,898 (63.81%) 90,056 (57.57%) 11,083 (53.65%) 14,661 (53.31%) 64,312 (59.40%)
Screening history (ﬁrst dose)
First dose received prior to year of ﬁrst screen 71,756 (45.87%) 6938 (33.58%) 10,565 (38.42%) 54,253 (50.11%)
First dose received after year of ﬁrst screen 84,667 (54.13%) 13,720 (66.42%) 16,936 (61.58%) 54,011 (49.89%)
Screening history (Final dose)
Final dose received prior to year of ﬁrst screen 60,934 (38.95%) 6938 (33.59%) 8638 (31.41%) 45,358 (41.90%)
Final dose received after year of ﬁrst screen 95,489 (61.05%) 13,720 (66.41%) 18,863 (68.59%) 62,906 (58.10%)
Age commenced vaccination (years)
r16 19,353 (12.37%) 668 (3.23%) 1541 (5.60%) 17,144 (15.84%)
17–19 30,055 (19.21%) 2790 (13.51%) 4158 (15.12%) 23,107 (21.34%)
20–23 59,377 (37.96%) 8941 (43.28%) 11,987 (43.59%) 38,449 (35.51%)
24þ 47,638 (30.45%) 8260 (39.98%) 9814 (35.69%) 29,564 (27.31%)
Year entered cohort
2007 58,834 (44.22%) 8949 (5.72%) 3802 (18.40%) 2933 (10.67%) 2214 (2.05%)
2008 13,992 (10.52%) 69,914 (44.70%) 7349 (35.57%) 10,905 (39.65%) 51,660 (47.72%)
2009 17,267 (12.98%) 39,390 (25.53%) 5627 (27.24%) 8339 (30.32%) 25,964 (23.98%)
2010 19,923 (14.97%) 19,146 (12.24%) 2226 (10.77%) 2895 (10.53%) 14,025 (12.95%)
2011 23,039 (17.32%) 18,484 (11.82%) 1655 (8.01%) 2428 (8.83%) 14,401 (13.30%)
Cytological abnormalities diagnosed on entry into cohort
Negative 73,016 (88.49%) 52,555 (88.78%) 5869 (87.49%) 7382 (88.23%) 39,304 (89.08%)
Low-grade 7846 (9.51%) 5727 (9.67%) 697 (10.39%) 824 (9.85%) 4206 (9.53%)
High-grade
Possible 795 (0.96%) 499 (0.84%) 79 (1.18%) 81 (0.97%) 339 (0.77%)
Deﬁnite 824 (1.00%) 406 (0.69%) 63 (0.94%) 78 (0.93%) 265 (0.60%)
Endocervical 34 (0.04%) 10 (0.02%) 0 (0%) 2 (0.02%) 8 (0.02%)
Note: 426 observations categorised as ‘Not Clinically Complete’ are excluded. Entry into the cohort was at ﬁrst Pap test, or 1 April 2007 if screened before this date. Missing
data on 2079 women excluded.
a Count is of women; “unvaccinated” refers to women screened who did not receive any dose of HPV vaccine; “completely vaccinated” refers to women who were
clinically completely vaccinated with three doses of HPV vaccine.
b Women were allocated to a remoteness area based on their postcode of usual residence, according to the Australian Standard Geographic Classiﬁcation (ASGC) for
2006. Missing data on 140 women excluded.
c Women were allocated to a socioeconomic status (SES) groups based on their postcode of usual residence, according to the Australian Bureau of Statistics Socio-
Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage [17]. Missing data on 320 women excluded.
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have provided the opportunity to undertake early assessments of
vaccination impact. We have taken advantage of the relatively
large numbers of women in the population who did not complete
their vaccine courses to assess whether there is any evidence, ﬁve
years after the commencement of the program, that less than
three doses of vaccine provide any protection against cervical
disease. We found that for women who were vaccinated before
commencing screening (an indicator that they were less likely to
be sexually active and therefore not already exposed to HPV prior
to vaccination), that one or two doses were associated with lower
Table 2
Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated women relative to their vaccination status at ﬁrst screen (ﬁnal
dose of vaccine before, ﬁnal dose of vaccine after or unvaccinated).
Outcome Vaccination
relative to ﬁrst screen
Number of
women /women-doses
Number of
abnormalities
Ratea Hazard ratiob
Histological abnormalities
Any high gradec Unvaccinated 133,055 3140 7.81 1
Vaccinated (unadjusted) Before 0.82 (0.75–0.89)
After 0.96 (0.91–1.02)
Vaccinated (adjusted) Before 60,934 678 6.44 0.86 (0.78–0.94)
After 95,489 2402 7.60 0.95 (0.90–1.00)
1 Dose Before 6938 124 9.28 1.19 (0.99–1.43)
After 13,720 408 8.78 1.10 (0.99–1.22)
2 Doses Before 8638 142 9.30 1.21 (1.02–1.44)
After 18,863 548 8.96 1.12 (1.02–1.23)
1 or 2 Doses Before 15,576 266 9.29 1.20 (1.06–1.37)
After 32,583 956 8.88 1.11 (1.03–1.20)
Complete Before 45,358 412 5.37 0.71 (0.64–0.80)
After 62,906 1446 6.94 0.87 (0.82–0.93)
CIN3/AISc Unvaccinated 133,055 1726 4.26 1
Vaccinated (unadjusted) Before 0.85 (0.75–0.96)
After 0.96 (0.89–1.03)
Vaccinated (adjusted) Before 60,934 343 3.24 0.87 (0.77–0.99)
After 95,489 1327 4.17 0.95 (0.88–1.02)
1 Dose Before 6938 78 5.81 1.41 (1.12–1.77)
After 13,720 216 4.60 1.04 (0.91–1.20)
2 Doses Before 8638 72 4.68 1.17 (0.92–1.48)
After 18,863 305 4.95 1.12 (0.99–1.27)
1 or 2 Doses Before 15,576 150 5.21 1.28 (1.08–1.52)
After 32,583 521 4.80 1.09 (0.99–1.20)
Complete Before 45,358 193 2.51 0.69 (0.58–0.81)
After 62,906 806 3.85 0.87 (0.80–0.95)
CIN2c Unvaccinated 133,055 1607 3.97 1
Vaccinated (unadjusted) Before 0.79 (0.71–0.89)
After 0.99 (0.92–1.06)
Vaccinated (adjusted) Before 60,934 377 3.56 0.85 (0.75–0.96)
After 95,489 1241 3.90 0.97 (0.90–1.05)
1 Dose Before 6938 54 4.01 0.98 (0.75–1.29)
After 13,720 220 4.70 1.17 (1.02–1.35)
2 Doses Before 8638 77 5.01 1.22 (0.97–1.54)
After 18,863 283 4.59 1.14 (1.01–1.30)
1 or 2 Doses Before 15,576 131 4.54 1.11 (0.92–1.33)
After 32,583 503 4.64 1.16 (1.05–1.28)
Complete Before 45,358 246 3.20 0.75 (0.65–0.86)
After 62,906 738 3.52 0.88 (0.81–0.96)
Cytological abnormalities
High-grade cytologyd Unvaccinated 133,055 3000 7.46 1
Vaccinated (unadjusted) Before 0.54 (0.48–0.60)
After 1.18 (1.13–1.25)
Vaccinated (adjusted) Before 60,934 404 3.81 0.53 (0.48–0.60)
After 95,489 2834 8.98 1.17 (1.11–1.23)
1 Dose Before 6938 44 3.25 0.44 (0.32–0.59)
After 13,720 390 8.36 1.09 (0.98–1.21)
2 Doses Before 8638 72 4.67 0.63 (0.50–0.80)
After 18,863 565 9.22 1.20 (1.09–1.31)
1 or 2 Doses Before 15,576 116 4.01 0.54 (0.45–0.65)
After 32,583 955 8.85 1.15 (1.07–1.24)
Complete Before 45,358 288 3.74 0.53 (0.47–0.60)
After 62,906 1879 9.05 1.17 (1.11–1.25)
Low-grade cytologyc Unvaccinated 133,055 6499 16.48 1
Vaccinated (unadjusted) Before 0.68 (0.64–0.72)
After 1.25 (1.21–1.30)
Vaccinated (adjusted) Before 60,934 1298 12.35 0.66 (0.62–0.71)
After 95,489 6367 20.58 1.25 (1.20–1.29)
1 Dose Before 6938 114 8.48 0.48 (0.40–0.58)
After 13,720 851 18.56 1.13 (1.05–1.21)
2 Doses Before 8638 143 9.32 0.52 (0.44–0.61)
After 18,863 1196 19.88 1.21 (1.13–1.28)
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rates of high grade and low grade cytology outcomes. By prolong-
ing the interval until outcomes were counted (allowing prevalent
disease to resolve or be treated), we also found evidence that
partial vaccination courses provide protection against high grade
histological disease.
Our data add to the current evidence by noting that, even when
given to a sexually active population using a conventional dosing
schedule, some evidence of vaccine effect on cervical abnormal-
ities can be observed from partial vaccination. It is consistent with
ﬁndings from another Australian study, in which Crowe et al.
estimated vaccine effectiveness of 21% against high-grade cervical
disease in Queensland women vaccinated with two doses attending
for their ﬁrst Pap test [18]. A study of females vaccinated in the
school program in British Columbia found signiﬁcant reduction in
high-grade disease in vaccine eligible cohorts but individual dose
data was not utilised so no assessment of the relative impact of
partial versus complete vaccination courses was made [19]. Swedish
data suggest considerable effectiveness against genital warts from
less than three doses of a conventional three-dose schedule [20].
Studies from Denmark have also demonstrated effectiveness of
quadrivalent HPV vaccine against cervical lesions [21,22] but, in the
case of genital warts, suggest that each dose provides an additional
(and therefore necessary) degree of protection when using a stan-
dard three-dose schedule [23]. In contrast, data from the Costa Rica
trial of the more immunogenic bivalent HPV vaccine suggested that
less than three doses of that vaccine may be as effective as three,
ﬁnding equally high levels of efﬁcacy against disease despite lower
but sustained antibody titres induced by partial vaccination [24,25].
Interestingly early data from Scotland did not detect a signiﬁcant
effect of partial bivalent vaccination on high grade CIN in young
women attending for their ﬁrst screens [26].
The main strengths of our analysis lie in the use of compre-
hensive high quality population based data sources. The greatest
limitation to our analyses is an inability to completely control for
confounding between the groups of women. This is not a rando-
mised study and the available demographic data indicate that
women differed signiﬁcantly according to their vaccination status.
Most notably those who only ever completed one or two doses of
vaccine were screening participants at an earlier age (suggesting
earlier onset of sexual activity) than vaccine completers or
unvaccinated women, suggesting that they may have a higher
underlying risk of HPV infection. This is supported by our ﬁnding
that these groups had signiﬁcantly higher rates of high grade
histology diagnoses in the summary estimates, and of cytological
abnormalities when vaccine was given after screening commence-
ment, than unvaccinated women (Table 2). Notably however in the
two youngest age strata (16 and under and 17–19 years (Tables A.1
and A.2, Appendix A)), hazard ratios for histological outcomes in
partially vaccinated women were one or below one, suggesting
Table 2 (continued )
Outcome Vaccination
relative to ﬁrst screen
Number of
women /women-doses
Number of
abnormalities
Ratea Hazard ratiob
1 or 2 Doses Before 15,576 257 8.93 0.50 (0.44–0.57)
After 32,583 2047 19.31 1.17 (1.11–1.23)
Complete Before 45,358 1041 13.64 0.73 (0.68–0.78)
After 62,906 4320 21.25 1.28 (1.23–1.33)
Note: 426 observations listed as ‘Not Clinically Complete’ are not included.
All high-grade histology deﬁned as CIN2, CIN3, AIS and mixed CIN3/AIS.
High-grade cytology deﬁned as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell carcinoma,
possible high-grade endocervical glandular lesion, AIS, AIS with possible microinvasion/invasion and adenocarcinoma.
Low-grade cytology deﬁned as possible low-grade squamous intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain signiﬁcance.
Unvaccinated refers to women screened who did not receive any dose of HPV vaccine; completely vaccinated refers to women who were clinically completely vaccinated
with three doses of HPV vaccine.
a Rate per 1000 person-years.
b Hazard ratio adjusted for age in 2007, remoteness and socioeconomic status.
c Age in 2007 ﬁtted as a categorical variable (i.e. o¼16, 17–19, 20–23 and 24þ).
d Age in 2007 ﬁtted as a continuous variable.
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these demographic differences in risk proﬁle can be overcome
when vaccine is given at a young age. Our ﬁnding that a greater
impact on cytology of partial doses was seen in older women
rather than in the youngest may be due to less stable estimates of
vaccine impact in younger women due to small numbers. Con-
versely the ﬁnding that suggestion of protection against high
grade histology in the youngest women may be because young
women are more likely to have HPV16 as the cause of high grade
disease [27,28] and because young women produce higher anti-
body responses which may mean they can derive a greater beneﬁt
from partial vaccination than older women.
The greater relative impact on cytological outcomes, than on
high-grade histologically conﬁrmed disease, may partly be due to
our greater power to detect differences in rates of cytological
abnormalities because of their much higher frequency. In the
Australian screening program, only a small subset of women
proceed to colposcopy and, if required, biopsy. An additional and
important factor that may explain the differences is the expected
time course between vaccine impacts on infection related outcomes
compared to high-grade disease outcomes which take longer after
initial infection to develop. Low-grade cytology is a manifestation of
acute HPV infection, so differences in incidence would be expected
to occur rapidly after vaccination. Whilst most high-grade cytology
does predict the presence of underlying high-grade pathology, it is
imperfect with a positive predictive value of 79% in Victoria [29]. If
21% of high-grade cytology is in fact misclassiﬁed then this may be
why an impact of partial vaccination was observed overall for high-
grade cytology but not histology amongst o3 dose vaccine reci-
pients. Additionally there is a lag time between high-grade cytology
diagnosis and eventual diagnosis at biopsy, meaning that women
diagnosed with high-grade cytology in the last months of the study
may not have had their biopsies by the end of the study period. As
shown in the study, the longer the interval between vaccination and
outcome measurement, the stronger the effect of vaccination,
meaning that the last period of the study is in fact when the
highest vaccination impact would be expected. This is consistent
with the ﬁndings of Hariri et al., who used the indirect cohort
method to estimate vaccine effectiveness against HPV16/18 attrib-
uted high grade CIN among women in sentinel populations in the
USA [30]. They found a clear relationship between vaccine effec-
tiveness and time since vaccination, with effectiveness increasing
over time. There was no signiﬁcant effectiveness on CIN3/AIS
lesions of 1 or more doses of HPV vaccine until 3 years post
vaccination (after 2 years for CIN2þ) in this similar population of
young women. However the study lacked power to explore effec-
tiveness by number of doses received.
It is interesting to note that Pollock et al. in Scotland also
obtained odds ratios of high grade disease above 1.0 for partially
vaccinated women, supporting our hypothesis that partially vac-
cinated young women may be at a somewhat higher underlying
risk of HPV, possibly relating to demographic or behavioural
characteristics which are also correlated with not completing the
vaccine course [26]. Hariri et al. also noted prevalence ratios
greater than one in young women in the ﬁrst year post vaccina-
tion, again indicating the high rates of prevalent infection in young
women [30]. We were not able to control for age at ﬁrst
intercourse or number of sexual partners in this population based
data set, although we used age and stratiﬁcation by vaccination
relative to screening commencement (as screening should only
commence at least two years after ﬁrst intercourse) to partially
control for likelihood of sexual activity/number of partners.
Analysis of national HPV vaccine register data has previously
found an association between socioeconomic status and course
completion, with ﬁrst dose uptake equal across socioeconomic
strata but dose 2 and 3 completion rates lower in the lowest
socioeconomic groups [31]. We adjusted for socioeconomic status
in our analysis. A study of 1139 young women in NSW, Australia,
recruited to a cohort following a negative Pap test, found that HPV
vaccinated women were more likely to be single, nulliparous,
alcohol drinkers, had fewer lifetime sexual partners but were more
likely to have a history of non-HPV STI, and were more likely to be
using oral contraceptives [32]. There was no association with
educational attainment. These factors can thus said to be asso-
ciated with decision making to receive HPV vaccination in young
adult women in the context of the national catch up program – it
is less likely that these factors relate to vaccination within the
school cohorts. Unfortunately, as these data were collected whilst
the catch up program was still ongoing, factors associated with
course completion could not be examined.
As partially vaccinated women were earlier screeners, they also
had more opportunity for detection of lesions. During the catch up
vaccination program there was a signiﬁcant amount of coincident
screening and vaccination, with 11% of vaccinated women having
their ﬁrst screen during the vaccination course [10]. There is thus a
possible detection bias, with vaccinated women more likely to have
abnormalities detected. In the present analysis, outcomes diagnosed
during the vaccination course were censored from the analysis and
the average number of screening tests did not vary greatly between
the groups of women in the study (Table 1). During this period in
Australia, the incidence of high grade abnormalities peaked in
women aged 20–24 years [33]. Because the median age of ﬁrst
intercourse in Australia is 16 years, most of the vaccinated women in
our cohort of screening women are likely to have been sexually
active prior to vaccination. As the HPV vaccine works by preventing
infection and does not treat existing infection, discerning the effect
of the vaccine in this population is difﬁcult. It is encouraging that,
similar to the increasing vaccine effectiveness over time observed in
the ITT analyses of the original vaccine trials, we were able to discern
some evidence of increasing effectiveness over time. By 2012 the
overall rates of high grade disease in young Australian women had
fallen in both the o20 and the 20–24 year old age group to such an
extent that peak rates are now in the 25–29 year old age group for
the ﬁrst time ever [11]. A repeated analysis using data from 2012
onwards would be useful to monitor rates by vaccination status in
upcoming cohorts of young women.
Other limitations include some underreporting to the register
of vaccine doses, meaning that some women with incomplete
courses may actually have received further doses. This would
lead to an overestimate of the effect of partial vaccination. A
national mobile phone survey suggested that nationally the
degree of under reporting to the register is by about 5%/10%/
15% for doses 1/2/3, respectively, in adult women (aged 18–26
during the catch up program) [5]. Under notiﬁcation is much less
for younger females as school reporting is virtually complete and
Victorian school vaccinees incomplete on the register are sent
reminders asking them to either complete the course or notify
the register if they have received further doses (for example from
their general practitioner) [34]. The data linkage undertaken was
deterministic as no unique identiﬁer was available for use and we
were not permitted to use identiﬁed data for linkage under
existing legislation. Hopefully in the future the use of the unique
healthcare identiﬁer on national health data sets in Australia, as
well as revised legislation for the cervical screening registers to
allow data to be used for data linkage, will result in datasets
being linked with better certainty that records are correctly
matched.
5. Conclusions
In summary we have observed an impact of both complete
vaccination courses and incomplete vaccination courses on
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cervical disease in Victorian women, despite many being sexually
active prior to vaccination. At this stage our data support an effect
of partial vaccination, although protection does not appear to be
equivalent to that provided by three doses. We anticipate, as our
analysis of the ﬁrst 5 years of screening data following the start of
the vaccination program suggests, that the effects of vaccination
will increase over time. Females vaccinated prior to sexual debut
will commence screening and women already infected prior to
vaccination will clear those infections or have them removed
through treatment, increasing the differential incident rate of
vaccine-preventable HPV infection and disease to be observed
between vaccinated and unvaccinated women in future.
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Appendix A
Appendix A Tables A1-A.6
Table A.1
Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated women (16 years of age or younger) relative to their ﬁrst screen.
Outcome Vaccination relative
to ﬁrst screen
Number of
women/women-doses
No. of abnormalities Ratea Hazard ratiob
Histological abnormalities
Any high gradec Unvaccinated 8005 65 6.51 1
Vaccinated (unadjusted) Before 0.62 (0.44–0.88)
After 0.39 (0.16–0.97)
Vaccinated (adjusted) Before 13,756 65 4.14 0.61 (0.43–0.87)
After 697 5 2.51 0.38 (0.15–0.94)
1 Dose Before 681 5 5.63 0.83 (0.33–2.05)
After 116 1 3.13 0.47 (0.06–3.38)
2 Doses Before 1215 7 4.72 0.70 (0.32–1.53)
After 157 2 4.71 0.72 (0.17–2.94)
1 or 2 Doses Before 1896 12 5.06 0.75 (0.40–1.39)
After 273 3 4.03 0.61 (0.19–1.95)
Complete Before 11,860 53 3.98 0.59 (0.41–0.85)
After 424 2 1.60 0.24 (0.06–0.99)
CIN3/AISc Unvaccinated 8005 27 2.70 1
Vaccinated (unadjusted) Before 0.50 (0.28–0.88)
After 0.39 (0.09–1.65)
Vaccinated (adjusted) Before 13,756 22 1.40 0.48 (0.27–0.84)
After 697 2 1.00 0.38 (0.09–1.61)
1 Dose Before 681 3 3.37 1.20 (0.37–3.92)
After 116 1 3.13 1.16 (0.16–8.67)
2 Doses Before 1215 2 1.34 0.48 (0.11–2.03)
After 157 1 2.34 0.89 (0.12–6.72)
1 or 2 Doses Before 1896 5 2.10 0.75 (0.29–1.96)
After 273 2 2.67 1.01 (0.24–4.34)
Complete Before 11,860 17 1.27 0.43 (0.23–0.79)
After 424 0 0.00 –
CIN2c Unvaccinated 8005 39 3.90 1
Vaccinated (unadjusted) Before 0.75 (0.49–1.14)
After 0.52 (0.19–1.45)
Vaccinated (adjusted) Before 13,756 47 2.99 0.76 (0.49–1.16)
After 697 4 2.01 0.50 (0.18–1.41)
1 Dose Before 681 2 2.24 0.55 (0.13–2.27)
After 116 0 0.00 -
2 Doses Before 1215 6 4.04 1.00 (0.42–2.38)
After 157 2 4.71 1.18 (0.28–4.94)
1 or 2 Doses Before 1896 8 3.37 0.83 (0.39–1.78)
After 273 2 2.68 0.67 (0.16–2.78)
Complete Before 11,860 39 2.93 0.74 (0.48–1.16)
After 424 2 1.60 0.40 (0.10–1.67)
Cytological abnormalities
High-grade cytologyd Unvaccinated 8005 47 4.69 1
Vaccinated (unadjusted) Before 0.64 (0.43–0.95)
After 0.98 (0.47–2.05)
Vaccinated (adjusted) Before 13,756 49 3.12 0.64 (0.43–0.96)
After 697 8 4.03 0.92 (0.43–1.94)
1 Dose Before 681 4 4.49 0.97 (0.35–2.70)
After 116 2 6.32 1.41 (0.34–5.87)
2 Doses Before 1215 9 6.05 1.27 (0.62–2.58)
After 157 5 11.88 2.80 (1.10–7.08)
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Table A.1 (continued )
Outcome Vaccination relative
to ﬁrst screen
Number of
women/women-doses
No. of abnormalities Ratea Hazard ratiob
1 or 2 Doses Before 1896 13 5.46 1.16 (0.63–2.14)
After 273 7 9.50 2.18 (0.98–4.85)
Complete Before 11,860 36 2.70 0.55 (0.35–0.86)
After 424 1 0.80 0.18 (0.03–1.32)
Low-grade cytologyc Unvaccinated 8005 140 14.13 1
Vaccinated (unadjusted) Before 0.83 (0.67–1.03)
After 1.79 (1.27–2.52)
Vaccinated (adjusted) Before 13,756 189 12.10 0.81 (0.66–1.01)
After 697 44 22.86 1.79 (1.27–2.51)
1 Dose Before 681 10 11.26 0.82 (0.43–1.55)
After 116 6 19.45 1.49 (0.65–3.38)
2 Doses Before 1215 10 6.74 0.48 (0.25–0.90)
After 157 12 29.65 2.39 (1.31–4.34)
1 or 2 Doses Before 1896 20 8.43 0.60 (0.38–0.96)
After 273 18 25.24 1.99 (1.21–3.25)
Complete Before 11,860 169 12.76 0.85 (0.68–1.06)
After 424 26 21.47 1.67 (1.10–2.55)
Note: 426 observations listed as ‘Not Clinically Complete’ are not included. All high grade histology deﬁned as CIN2, CIN3, AIS and mixed CIN3/AIS. High-grade cytology
deﬁned as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell carcinoma, possible high-grade
endocervical glandular lesion, AIS, AIS with possible microinvasion/invasion and adenocarcinoma. Low-grade cytology deﬁned as possible low-grade squamous
intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain signiﬁcance. Unvaccinated refers to women screened who did not receive any dose of HPV
vaccine; completely vaccinated refers to women who were clinically completely vaccinated with three doses of HPV vaccine.
a Rate per 1000 person-years.
b Hazard ratio adjusted for age in 2007, remoteness and SES.
c Age in 2007 ﬁtted as a categorical variable (i.e. o¼16, 17–19, 20–23 and 24þ).
d Age in 2007 ﬁtted as a continuous variable.
Table A.2
Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated women (17–19 years of age) relative to their ﬁrst screen.
Outcome Vaccination
relative to ﬁrst screen
Number of
women/women-doses
No. of abnormalities Ratea Hazard ratiob
Histological abnormalities
Any high gradec Unvaccinated 23,066 435 8.22 1
Vaccinated (unadjusted) Before 0.71 (0.61–0.82)
After 0.88 (0.76–1.03)
Vaccinated (adjusted) Before 25,014 270 5.78 0.69 (0.59–0.80)
After 11,222 264 7.25 0.85 (0.73–0.99)
1 Dose Before 2078 34 8.58 1.02 (0.72–1.45)
After 1610 35 6.74 0.78 (0.55–1.10)
2 Doses Before 2797 45 8.67 1.01 (0.74–1.37)
After 2147 67 10.08 1.18 (0.91–1.53)
1 or 2 Doses Before 4875 79 8.63 1.01 (0.79–1.29)
After 3757 102 8.62 1.00 (0.81–1.25)
Complete Before 20,139 191 5.08 0.61 (0.51–0.72)
After 7465 162 6.60 0.78 (0.65–0.93)
CIN3/AISc Unvaccinated 23,066 202 3.78 1
Vaccinated (unadjusted) Before 0.73 (0.58–0.91)
After 0.89 (0.71–1.11)
Vaccinated (adjusted) Before 25,014 129 2.75 0.70 (0.56–0.88)
After 11,222 126 3.44 0.86 (0.69–1.08)
1 Dose Before 2078 22 5.53 1.38 (0.89–2.15)
After 1610 15 2.87 0.68 (0.39–1.16)
2 Doses Before 2797 24 4.60 1.11 (0.72–1.70)
After 2147 34 5.07 1.25 (0.87–1.80)
1 or 2 Doses Before 4875 46 5.00 1.23 (0.89–1.70)
After 3757 49 4.11 1.00 (0.73–1.38)
Complete Before 20,139 83 2.20 0.56 (0.44–0.73)
After 7465 77 3.12 0.80 (0.61–1.04)
CIN2c Unvaccinated 23,066 263 4.94 1
Vaccinated (unadjusted) Before 0.70 (0.57–0.85)
After 0.89 (0.73–1.08)
Vaccinated (adjusted) Before 25,014 161 3.43 0.69 (0.56–0.84)
After 11,222 159 4.35 0.86 (0.70–1.05)
1 Dose Before 2078 13 3.26 0.66 (0.38–1.15)
After 1610 22 4.22 0.84 (0.54–1.30)
2 Doses Before 2797 24 4.60 0.92 (0.61–1.41)
After 2147 40 5.99 1.18 (0.84–1.65)
1 or 2 Doses Before 4875 37 4.02 0.81 (0.57–1.14)
After 3757 62 5.21 1.03 (0.78–1.36)
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Table A.2 (continued )
Outcome Vaccination
relative to ﬁrst screen
Number of
women/women-doses
No. of abnormalities Ratea Hazard ratiob
Complete Before 20,139 124 3.29 0.66 (0.53–0.81)
After 7465 97 3.93 0.78 (0.61–0.98)
Cytological abnormalities
High-grade cytologyd Unvaccinated 23,066 358 6.73 1
Vaccinated (unadjusted) Before 0.59 (0.50–0.71)
After 1.36 (1.17–1.58)
Vaccinated (adjusted) Before 25,014 190 4.05 0.59 (0.50–0.71)
After 11,222 343 9.45 1.33 (1.14–1.54)
1 Dose Before 2078 14 3.50 0.48 (0.28–0.82)
After 1610 39 7.50 1.03 (0.74–1.44)
2 Doses Before 2797 23 4.40 0.61 (0.40–0.93)
After 2147 72 10.83 1.50 (1.16–1.93)
1 or 2 Doses Before 4875 37 4.01 0.56 (0.40–0.78)
After 3757 111 9.37 1.29 (1.04–1.60)
Complete Before 20,139 153 4.06 0.60 (0.50–0.73)
After 7465 232 9.49 1.35 (1.14–1.59)
Low-grade cytologyc Unvaccinated 23,066 977 18.74 1
Vaccinated (unadjusted) Before 0.83 (0.75–0.91)
After 1.40 (1.28–1.53)
Vaccinated (adjusted) Before 25,014 738 15.91 0.81 (0.74–0.90)
After 11,222 940 26.65 1.39 (1.27–1.52)
1 Dose Before 2078 47 11.87 0.61 (0.46–0.82)
After 1610 107 21.01 1.10 (0.90–1.34)
2 Doses Before 2797 71 13.71 0.70 (0.55–0.89)
After 2147 144 22.05 1.15 (0.96–1.37)
1 or 2 Doses Before 4875 118 12.91 0.66 (0.55–0.80)
After 3757 251 21.59 1.13 (0.98–1.29)
Complete Before 20,139 620 16.64 0.85 (0.77–0.94)
After 7465 689 29.14 1.51 (1.37–1.67)
Note: 426 observations listed as ‘Not Clinically Complete’ are not included. All high grade histology deﬁned as CIN2, CIN3, AIS and mixed CIN3/AIS. High-grade cytology
deﬁned as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell carcinoma, possible high-grade
endocervical glandular lesion, AIS, AIS with possible microinvasion/invasion and adenocarcinoma. Low-grade cytology deﬁned as possible low-grade squamous
intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain signiﬁcance. Unvaccinated refers to women screened who did not receive any dose of HPV
vaccine; completely vaccinated refers to women who were clinically completely vaccinated with three doses of HPV vaccine.
a Rate per 1000 person-years.
b Hazard ratio adjusted for age in 2007, remoteness and SES.
c Age in 2007 ﬁtted as a categorical variable (i.e. o¼16, 17–19, 20–23 and 24þ).
d Age in 2007 ﬁtted as a continuous variable.
Table A.3
Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated women (20–23 years of age) relative to their ﬁrst screen.
Outcome Vaccination
relative to ﬁrst screen
Number of women/women-doses No. of abnormalities Ratea Hazard ratiob
Histological abnormalities
Any high gradec Unvaccinated 50,255 1321 8.43 1
Vaccinated (unadjusted) Before 0.95 (0.82–1.09)
After 1.01 (0.94–1.10)
Vaccinated (adjusted) Before 15,303 230 7.82 0.95 (0.82–1.09)
After 45,689 1248 8.39 1.00 (0.92–1.08)
1 Dose Before 2820 55 9.75 1.16 (0.88–1.53)
After 6531 227 10.49 1.25 (1.09–1.44)
2 Doses Before 3182 64 10.88 1.33 (1.03–1.71)
After 9284 279 9.42 1.12 (0.98–1.28)
1 or 2 Doses Before 6002 119 10.32 1.25 (1.03–1.51)
After 15,815 506 9.87 1.18 (1.06–1.30)
Complete Before 9301 111 6.21 0.75 (0.62–0.91)
After 29,874 742 7.62 0.91 (0.83–0.99)
CIN3/AISc Unvaccinated 50,255 707 4.47 1
Vaccinated (unadjusted) Before 0.91 (0.75–1.11)
After 0.99 (0.89–1.10)
Vaccinated (adjusted) Before 15,303 121 4.09 0.92 (0.76–1.12)
After 45,689 665 4.44 0.98 (0.88–1.09)
1 Dose Before 2820 34 5.99 1.30 (0.91–1.85)
After 6531 121 5.53 1.22 (1.00–1.48)
2 Doses Before 3182 31 5.22 1.18 (0.82–1.69)
After 9284 147 4.92 1.09 (0.91–1.30)
1 or 2 Doses Before 6002 65 5.60 1.24 (0.96–1.60)
After 15,815 268 5.18 1.14 (0.99–1.32)
Complete Before 9301 56 3.12 0.71 (0.54–0.93)
After 29,874 397 4.05 0.90 (0.79–1.01)
CIN2c Unvaccinated 50,255 699 4.42 1
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Table A.3 (continued )
Outcome Vaccination
relative to ﬁrst screen
Number of women/women-doses No. of abnormalities Ratea Hazard ratiob
Vaccinated (unadjusted) Before 0.98 (0.81–1.19)
After 1.04 (0.93–1.16)
Vaccinated (adjusted) Before 15,303 123 4.16 0.98 (0.80–1.19)
After 45,689 663 4.43 1.02 (0.92–1.13)
1 Dose Before 2820 25 4.39 1.03 (0.69–1.54)
After 6531 121 5.54 1.28 (1.06–1.55)
2 Doses Before 3182 36 6.06 1.45 (1.03–2.02)
After 9284 149 4.99 1.14 (0.96–1.37)
1 or 2 Doses Before 6002 61 5.24 1.24 (0.95–1.62)
After 15,815 270 5.22 1.20 (1.04–1.39)
Complete Before 9301 62 3.45 0.80 (0.62–1.04)
After 29,874 393 4.01 0.92 (0.81–1.04)
Cytological abnormalities
High-grade cytologyd Unvaccinated 50,255 1223 7.79 1
Vaccinated (unadjusted) Before 0.51 (0.43–0.62)
After 1.22 (1.13–1.32)
Vaccinated (adjusted) Before 15,303 119 4.01 0.52 (0.43–0.62)
After 45,689 1413 9.51 1.20 (1.11–1.30)
1 Dose Before 2820 20 3.49 0.45 (0.29–0.70)
After 6531 199 9.14 1.16 (1.00–1.35)
2 Doses Before 3182 30 5.04 0.65 (0.45–0.93)
After 9284 280 9.43 1.19 (1.05–1.36)
1 or 2 Doses Before 6002 50 4.28 0.55 (0.41–0.73)
After 15,815 479 9.31 1.18 (1.06–1.31)
Complete Before 9301 69 3.83 0.49 (0.39–0.63)
After 29,874 934 9.62 1.22 (1.12–1.32)
Low-grade cytologyc Unvaccinated 50,255 2744 17.87 1
Vaccinated (unadjusted) Before 0.53 (0.47–0.60)
After 1.26 (1.20–1.32)
Vaccinated (adjusted) Before 15,303 277 9.39 0.53 (0.47–0.60)
After 45,689 3224 22.19 1.25 (1.18–1.31)
1 Dose Before 2820 43 7.55 0.43 (0.32–0.58)
After 6531 432 20.21 1.14 (1.03–1.26)
2 Doses Before 3182 49 8.25 0.47 (0.36–0.62)
After 9284 643 22.13 1.25 (1.15–1.37)
1 or 2 Doses Before 6002 92 7.91 0.45 (0.37–0.56)
After 15,815 1075 21.32 1.21 (1.12–1.29)
Complete Before 9301 185 10.35 0.58 (0.50–0.67)
After 29,874 2149 22.65 1.27 (1.20–1.34)
Note: 426 observations listed as ‘Not Clinically Complete’ are not included.
All high grade histology deﬁned as CIN2, CIN3, AIS and mixed CIN3/AIS. High-grade cytology deﬁned as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL
with possible microinvasion/invasion, squamous cell carcinoma, possible high-grade endocervical glandular lesion, AIS, AIS with possible microinvasion/invasion and
adenocarcinoma. Low-grade cytology deﬁned as possible low-grade squamous intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain signiﬁcance.
Unvaccinated refers to women screened who did not receive any dose of HPV vaccine; completely vaccinated refers to women who were clinically completely vaccinated
with three doses of HPV vaccine.
a Rate per 1000 person-years.
b Hazard ratio adjusted for age in 2007, remoteness and SES.
c Age in 2007 ﬁtted as a categorical variable (i.e. o¼16, 17–19, 20–23 and 24þ).
d Age in 2007 ﬁtted as a continuous variable.
Table A.4
Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated women (24–26 years of age) relative to their ﬁrst screen.
Outcome Vaccination
relative to ﬁrst screen
Number of
women/women-doses
No. of abnormalities Ratea Hazard ratiob
Histological abnormalities
Any high gradec Unvaccinated 51,729 1319 7.24 1
Vaccinated (unadjusted) Before 1.22 (1.01–1.49)
After 0.97 (0.89–1.06)
Vaccinated (adjusted) Before 6861 113 8.37 1.24 (1.02–1.50)
After 37,881 885 6.86 0.96 (0.88–1.04)
1 Dose Before 1359 30 10.48 1.53 (1.06–2.21)
After 5464 145 7.50 1.04 (0.88–1.24)
2 Doses Before 1444 26 9.58 1.41 (0.95–2.08)
After 7274 200 8.17 1.15 (0.99–1.33)
1 or 2 Doses Before 2803 56 10.04 1.47 (1.12–1.93)
After 12,738 345 7.88 1.10 (0.97–1.24)
Complete Before 4058 57 7.20 1.07 (0.82–1.40)
After 25,143 540 6.34 0.88 (0.80–0.98)
CIN3/AISc Unvaccinated 51,729 790 4.31 1
Vaccinated (unadjusted) Before 1.26 (0.98–1.61)
After 0.97 (0.87–1.08)
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Table A.5
Adjusted hazard ratiosa for high grade histology and CIN3/AIS histology for women receiving two doses, stratiﬁed by dose spacing 4¼6 monthsb and whether vaccination
was before or after screening commencement. Censorship time refers to lag times until counting of outcomes commences.
Vaccine status Vaccination
relative to
ﬁrst screen
Time between
doses
Hazard ratio Censoring time
1 Month 6 Months 12 Months 24 Months
Hazard ratio Hazard ratio Hazard ratio Hazard ratio
Any high grade histology Unvaccinated 1 1 1 1 1
2 doses Before o6 Months 1.25 (1.03–1.51) 1.13 (0.92–1.39) 0.81 (0.60–1.09) 0.88 (0.63–1.22) 0.92 (0.57–1.49)
After o6 Months 1.18 (1.06–1.30) 1.19 (1.07–1.32) 1.15 (1.01–1.30) 1.18 (1.03–1.35) 1.13 (0.95–1.34)
Before 4¼6 Months 1.05 (0.72–1.55) 0.94 (0.61–1.45) 0.81 (0.46–1.42) 0.96 (0.52–1.79) 1.38 (0.57–3.32)
After 4¼6 Months 0.96 (0.80–1.16) 1.01 (0.84–1.22) 1.12 (0.92–1.38) 1.15 (0.92–1.44) 1.04 (0.75–1.43)
CIN3/AIS Unvaccinated 1 1 1 1 1
2 doses Before o6 Months 1.19 (0.91–1.56) 1.02 (0.76–1.38) 0.62 (0.40–0.98) 0.61 (0.36–1.04) 0.58 (0.26–1.29)
After o6 Months 1.17 (1.02–1.34) 1.17 (1.02–1.35) 1.21 (1.03–1.42) 1.22 (1.03–1.44) 1.23 (0.99–1.52)
Before 4¼6 Months 1.08 (0.64–1.82) 1.01 (0.57–1.78) 0.87 (0.41–1.82) 1.23 (0.58–2.58) 1.97 (0.74–5.26)
After 4¼6 Months 0.99 (0.78–1.26) 1.01 (0.78–1.29) 1.17 (0.89–1.52) 1.18 (0.88–1.57) 1.13 (0.75–1.68)
a Adjusted for Age in 2007 (Categorized), ‘Remoteness’ and ‘SES’.
b 20,297 (73.8%) women with a ﬁnal dose status of two doses had dose two given within 6 months. 7204 (26.2%) women had the second dose administered 6 months or
more after dose one.
Table A.6
Impact of censoring time until end point assessment for high grade histology and CIN3/AIS. For partially vaccinated women who were vaccinated before commencing
screening, hazard ratios decrease over time.
Vaccination
relative to ﬁrst screen
Hazard ratio Censoring time
1 Month 6 Months 12 Months 24 Months
Hazard ratio Hazard ratio Hazard ratio Hazard ratio
Any high-grade Unvaccinated 1 1 1 1 1
Vaccinated (unadjusted) Before 0.82 (0.75–0.89) 0.74 (0.67–0.82) 0.58 (0.51–0.66) 0.64 (0.56–0.74) 0.72 (0.59–0.88)
After 0.96 (0.91–1.02) 1.01 (0.96–1.07) 1.12 (1.06–1.19) 1.10 (1.03–1.18) 1.01 (0.93–1.10)
Vaccinated (adjusted) Before 0.86 (0.78–0.94) 0.77 (0.70–0.85) 0.59 (0.52–0.67) 0.66 (0.57–0.76) 0.72 (0.58–0.88)
After 0.95 (0.90–1.00) 0.99 (0.94–1.05) 1.10 (1.04–1.17) 1.09 (1.02–1.16) 0.99 (0.91–1.08)
1 Dose Before 1.19 (0.99–1.43) 1.03 (0.84–1.27) 0.66 (0.49–0.89) 0.65 (0.46–0.93) 0.54 (0.30–0.95)
After 1.10 (0.99–1.22) 1.07 (0.96–1.20) 1.02 (0.90–1.16) 1.00 (0.87–1.15) 0.89 (0.74–1.08)
2 Doses Before 1.21 (1.02–1.44) 1.09 (0.90–1.32) 0.81 (0.62–1.05) 0.89 (0.67–1.20) 1.00 (0.65–1.52)
After 1.12 (1.02–1.23) 1.14 (1.04–1.25) 1.14 (1.02–1.27) 1.17 (1.04–1.32) 1.11 (0.95–1.29)
1 or 2 Doses Before 1.20 (1.06–1.37) 1.06 (0.92–1.23) 0.74 (0.60–0.90) 0.78 (0.62–0.98) 0.76 (0.54–0.89)
After 1.11 (1.03–1.20) 1.11 (1.03–1.20) 1.09 (1.00–1.19) 1.10 (1.00–1.20) 1.01 (0.89–1.15)
Complete Before 0.71 (0.64–0.80) 0.65 (0.57–0.73) 0.53 (0.45–0.62) 0.61 (0.51–0.72) 0.70 (0.55–0.89)
After 0.87 (0.82–0.93) 0.94 (0.88–1.00) 1.11 (1.04–1.19) 1.09 (1.01–1.17) 0.98 (0.89–1.09)
CIN3/AIS Unvaccinated 1 1 1 1 1
Vaccinated (unadjusted) Before 0.85 (0.75–0.96) 0.83 (0.67–1.03) 0.49 (0.36–0.68) 0.55 (0.45–0.68) 0.57 (0.42–0.77)
After 0.96 (0.89–1.03) 1.05 (0.94–1.17) 1.21 (1.07–1.36) 1.13 (1.03–1.23) 1.06 (0.95–1.19)
Vaccinated (adjusted) Before 0.87 (0.77–0.99) 0.79 (0.69–0.91) 0.52 (0.43–0.63) 0.55 (0.45–0.68) 0.56 (0.42–0.76)
After 0.95 (0.88–1.02) 0.98 (0.91–1.06) 1.12 (1.03–1.22) 1.11 (1.01–1.21) 1.04 (0.93–1.16)
1 Dose Before 1.41 (1.12–1.77) 1.19 (0.92–1.54) 0.62 (0.41–0.95) 0.56 (0.33–0.93) 0.39 (0.16–0.95)
After 1.04 (0.91–1.20) 1.03 (0.89–1.19) 1.03 (0.87–1.22) 0.98 (0.82–1.18) 0.95 (0.75–1.20)
2 Doses Before 1.17 (0.92–1.48) 1.02 (0.78–1.33) 0.68 (0.46–1.00) 0.74 (0.48–1.14) 0.81 (0.43–1.51)
After 1.12 (0.99–1.27) 1.13 (1.00–1.28) 1.20 (1.04–1.38) 1.21 (1.04–1.41) 1.21 (0.99–1.46)
1 or 2 Doses Before 1.28 (1.08–1.52) 1.10 (0.91–1.33) 0.65 (0.49–0.87) 0.65 (0.46–0.91) 0.60 (0.36–1.00)
After 1.09 (0.99–1.20) 1.09 (0.98–1.20) 1.13 (1.00–1.26) 1.11 (0.98–1.26) 1.09 (0.93–1.27)
Complete Before 0.69 (0.58–0.81) 0.65 (0.55–0.77) 0.46 (0.36–0.58) 0.51 (0.39–0.66) 0.55 (0.38–0.79)
After 0.87 (0.80–0.95) 0.93 (0.86–1.02) 1.12 (1.02–1.23) 1.11 (1.00–1.22) 1.01 (0.89–1.15)
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Appendix B
Appendix B Figs. B1–B5.
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